Aplastic Anemia in HIV: The Role of Epigenetic Modifications

Article · September 2024

1 author:

Emmanuel Ifeanyi Obeagu
Africa University
2,100 PUBLICATIONS **36,090** CITATIONS

SEE PROFILE

Elite Journal of Haematology. Volume 2 Issue 9(2024), Pp. 33-45

https://epjournals.com/journals/EJH

Aplastic Anemia in HIV: The Role of Epigenetic Modifications

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Aplastic anemia (AA) is a critical hematological condition characterized by the failure of bone marrow to produce adequate blood cells, leading to severe anemia, thrombocytopenia, and leukopenia. In individuals with Human Immunodeficiency Virus (HIV), the incidence and severity of AA are exacerbated by both direct viral effects and complex immune dysregulation. Recent research has illuminated the significant role of epigenetic modifications—such as DNA methylation, histone modifications, and non-coding RNAs—in the pathogenesis of AA within the context of HIV infection. These epigenetic changes disrupt normal hematopoiesis and immune function, contributing to the progression of the disease. DNA methylation and histone modifications can lead to the silencing or aberrant activation of genes critical for hematopoietic stem cell function and immune regulation. For instance, hypermethylation of gene promoters may inhibit the expression of key genes involved in cell proliferation and survival, while altered histone acetylation can affect chromatin accessibility and gene transcription. Non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), also play pivotal roles by regulating gene expression at multiple levels, further influencing the disease process in AA.

Keywords: *Aplastic Anemia, HIV, Epigenetic Modifications, DNA Methylation, Histone Modification*

Introduction

Aplastic anemia (AA) is a serious hematological disorder characterized by the bone marrow's failure to produce sufficient blood cells, resulting in severe anemia, thrombocytopenia, and leukopenia. This condition significantly impacts patient quality of life and poses substantial health

Citation: Obeagu EI. Aplastic Anemia in HIV: The Role of Epigenetic Modifications. *Elite Journal of Haematology, 2024; 2(9):* 33-45

risks. The etiology of AA is multifaceted, involving both intrinsic defects in hematopoietic stem cells (HSCs) and extrinsic factors such as autoimmune responses and environmental influences. Among the extrinsic factors, Human Immunodeficiency Virus (HIV) has been identified as a major contributor to the development and exacerbation of AA. HIV's impact on hematopoiesis is both direct, through viral invasion and damage, and indirect, via the alteration of immune responses.[1-5] The interplay between HIV and AA involves complex mechanisms that disrupt normal hematopoiesis. HIV infection can directly affect HSCs by inducing cell apoptosis and interfering with the bone marrow microenvironment. Additionally, HIV-related immune dysregulation, including the activation of autoreactive T cells and the production of pro-inflammatory cytokines, further contributes to the pathogenesis of AA. The resulting immune-mediated damage to hematopoietic cells exacerbates bone marrow failure, leading to the clinical manifestations of AA. Recent research has highlighted the crucial role of epigenetic modifications in the development and progression of AA, particularly in the context of HIV infection. Epigenetic modifications refer to changes in gene expression regulation that do not involve alterations in the DNA sequence itself but involve modifications to DNA and histone proteins. These changes can profoundly influence gene expression and cellular function, impacting processes such as hematopoiesis, immune regulation, and cellular stress responses.[6-10] DNA methylation is one of the primary epigenetic modifications involved in regulating gene expression. In AA, aberrant DNA methylation patterns can lead to the silencing of genes critical for hematopoietic cell function and survival. For instance, hypermethylation of promoter regions can inhibit the expression of genes involved in cell proliferation, differentiation, and apoptosis. In the context of HIV, such aberrations in DNA methylation can exacerbate the detrimental effects of the virus on hematopoietic cells, contributing to the development and progression of AA. Histone modifications are another key aspect of epigenetic regulation. Histone proteins, which package DNA into chromatin, can undergo various modifications such as acetylation, methylation, and phosphorylation. These modifications affect chromatin structure and gene accessibility. In AA, alterations in histone modifications can disrupt the expression of genes essential for normal hematopoiesis and immune function. For example, changes in histone acetylation or methylation patterns can impact the transcriptional regulation of genes involved in hematopoietic stem cell maintenance and differentiation.[11-15]

Non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), also play critical roles in regulating gene expression and cellular processes. In the context of AA associated with HIV, dysregulated expression of specific non-coding RNAs can contribute to disease pathogenesis. miRNAs, which regulate gene expression by binding to target mRNAs, can influence hematopoiesis and immune responses. lncRNAs, on the other hand, are involved in chromatin remodeling and gene transcription regulation. Abnormalities in these non-coding RNAs can impact the function of hematopoietic cells and immune responses, exacerbating the severity of AA.[16-20] The identification of epigenetic changes associated with HIV-related AA provides new avenues for therapeutic intervention. Targeting aberrant DNA methylation, histone modifications, and non-coding RNA expression offers potential strategies for correcting the underlying epigenetic dysregulation in AA. Epigenetic therapies, such as DNA methylation inhibitors and histone deacetylase inhibitors, have shown promise in other hematological disorders and could be explored for AA management. Additionally, non-coding RNA-based therapies, including miRNA mimics and inhibitors, offer novel approaches to modulating gene expression and improving hematopoietic function.[21-23]

Citation: Obeagu EI. Aplastic Anemia in HIV: The Role of Epigenetic Modifications. *Elite Journal of Haematology, 2024; 2(9):* 33-45

Epigenetic Modifications and Their Mechanisms

Epigenetic modifications are heritable changes in gene expression that occur without alterations to the DNA sequence itself. These modifications regulate various cellular processes by affecting chromatin structure and gene accessibility. They play a crucial role in development, cellular differentiation, and disease progression. In the context of aplastic anemia (AA) associated with HIV, understanding these modifications is key to unraveling the mechanisms underlying the disease and identifying potential therapeutic targets. DNA methylation involves the addition of a methyl group to the 5' position of cytosine residues within CpG dinucleotides. This modification typically leads to gene silencing by inhibiting the binding of transcription factors and promoting the formation of a repressive chromatin environment. In AA, abnormal DNA methylation patterns can lead to the silencing of genes critical for hematopoiesis and immune regulation. For example, hypermethylation of promoter regions in genes involved in cell cycle regulation or apoptosis can impair hematopoietic cell function, contributing to bone marrow failure.[24-28] Histones are proteins around which DNA is wrapped to form chromatin. The amino-terminal tails of histones can undergo various post-translational modifications, including acetylation, methylation, phosphorylation, and ubiquitination. These modifications alter chromatin structure and influence gene expression. Acetylation of histone lysine residues, primarily by histone acetyltransferases (HATs), is associated with transcriptional activation. This modification neutralizes the positive charge of histones, reducing their affinity for negatively charged DNA and making the chromatin more accessible for transcription. Conversely, histone deacetylation, performed by histone deacetylases (HDACs), leads to transcriptional repression by restoring the positive charge and promoting a closed chromatin configuration. Histone methylation involves the addition of methyl groups to lysine or arginine residues. Depending on the specific residues and the number of methyl groups added, histone methylation can either activate or repress gene transcription. For instance, methylation of histone H3 on lysine 4 (H3K4me) is associated with active transcription, while methylation on lysine 27 (H3K27me) is linked to gene repression.[29-32]

Non-coding RNAs (ncRNAs) are RNA molecules that do not code for proteins but play crucial roles in regulating gene expression. Two major types of ncRNAs relevant to AA are microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). miRNAs are small RNA molecules (~22 nucleotides) that regulate gene expression by binding to complementary sequences in target mRNAs, leading to their degradation or inhibition of translation. Dysregulation of miRNAs in AA can affect hematopoiesis and immune responses. For example, certain miRNAs may target genes involved in hematopoietic stem cell maintenance or immune modulation, impacting disease progression. lncRNAs are longer RNA molecules (>200 nucleotides) that can regulate gene expression through various mechanisms, including chromatin remodeling, interaction with transcription factors, and modulation of splicing. lncRNAs can influence hematopoiesis and immune responses by interacting with chromatin-modifying complexes and transcriptional machinery.[33-37]

Epigenetic modifications often work in concert to regulate gene expression. For example, DNA methylation can interact with histone modifications to establish and maintain repressive chromatin states. Similarly, non-coding RNAs can influence the deposition of epigenetic marks or recruit

chromatin-modifying enzymes to specific genomic regions. HIV infection can alter epigenetic landscapes in various ways. The virus can induce changes in DNA methylation and histone modifications, affecting genes involved in immune function and hematopoiesis. HIV-induced inflammation and immune dysregulation can further contribute to epigenetic changes, exacerbating the effects on bone marrow function and increasing the risk of AA. Targeting epigenetic modifications presents a promising approach for treating AA, especially in the context of HIV. Epigenetic therapies, such as DNA methylation inhibitors (e.g., azacitidine, decitabine) and histone deacetylase inhibitors (e.g., vorinostat, romidepsin), have shown efficacy in other hematological disorders and may offer therapeutic benefits for AA. Additionally, modulating non-coding RNA expression through miRNA mimics or inhibitors could provide novel strategies for correcting dysregulated gene expression in AA.[38-42]

DNA Methylation in Aplastic Anemia and HIV

DNA methylation is a key epigenetic mechanism that involves the addition of a methyl group to the 5' position of cytosine residues within CpG dinucleotides. This modification generally results in gene silencing by preventing the binding of transcription factors and promoting a compact chromatin structure that is less accessible for transcription. In the context of aplastic anemia (AA) and HIV infection, aberrant DNA methylation plays a significant role in disrupting normal hematopoiesis and contributing to disease pathogenesis. In AA, DNA methylation patterns are often disrupted, leading to the silencing of genes essential for hematopoietic cell function and survival. For instance, hypermethylation of promoter regions in genes involved in cell cycle regulation, apoptosis, and hematopoietic stem cell maintenance can impair the proliferation and differentiation of hematopoietic stem cells (HSCs). Studies have identified specific genes that are aberrantly methylated in AA, contributing to the pathogenesis of the disease. For example, genes like **TP53** and **RUNX1**, which are crucial for cell cycle control and hematopoiesis, respectively, may be subject to abnormal methylation in AA patients, leading to impaired bone marrow function and increased susceptibility to disease progression.[43-47] HIV infection exacerbates the impact of DNA methylation on hematopoiesis by inducing additional epigenetic changes. The virus can directly influence DNA methylation patterns in host cells through several mechanisms. HIV proteins, such as Tat and Vpr, have been shown to interact with host chromatin-modifying enzymes, potentially altering DNA methylation patterns and contributing to gene silencing. This can disrupt normal hematopoiesis and immune function, further complicating AA in HIV-infected individuals. Furthermore, HIV-induced chronic inflammation and immune dysregulation can also contribute to abnormal DNA methylation. The persistent inflammatory environment created by HIV infection can lead to global hypomethylation or localized hypermethylation of genes involved in immune responses and hematopoiesis. This dysregulation can exacerbate the effects of HIV on bone marrow function and increase the risk of developing AA.[48-52]

The mechanisms through which HIV influences DNA methylation in AA are complex and multifaceted. HIV-induced oxidative stress and inflammatory cytokines can affect the activity of DNA methyltransferases (DNMTs), the enzymes responsible for adding methyl groups to DNA. Changes in DNMT expression or activity can lead to altered DNA methylation patterns and contribute to the silencing of genes critical for hematopoiesis. Additionally, HIV can influence the

expression of non-coding RNAs, such as microRNAs (miRNAs), which play a role in regulating DNA methylation. For example, certain miRNAs can target DNMTs or their regulators, impacting DNA methylation patterns and gene expression. Dysregulation of these miRNAs in the context of HIV can further contribute to the epigenetic changes observed in AA. The identification of aberrant DNA methylation patterns in AA, particularly in the context of HIV infection, has important clinical implications. Methylation profiles can serve as biomarkers for disease diagnosis, prognosis, and treatment response. Additionally, targeting DNA methylation changes through therapeutic strategies, such as the use of DNA methylation inhibitors (e.g., azacitidine, decitabine), may offer new treatment options for AA patients, especially those with HIV-related complications.[53-57]

Histone Modifications in Aplastic Anemia

Histone modifications are pivotal in regulating gene expression by altering chromatin structure, which in turn affects the accessibility of DNA for transcription. These modifications include acetylation, methylation, phosphorylation, and ubiquitination of histone proteins. In aplastic anemia (AA), aberrant histone modifications play a significant role in disrupting hematopoiesis and contributing to disease pathology. Histone acetylation is typically associated with transcriptional activation. The addition of acetyl groups to lysine residues on histone tails by histone acetyltransferases (HATs) neutralizes the positive charge of histones, reducing their affinity for negatively charged DNA and thereby creating a more open chromatin structure conducive to transcription. Conversely, histone deacetylation, performed by histone deacetylases (HDACs), promotes a closed chromatin state that represses gene expression. In AA, disrupted acetylation patterns can impact genes involved in hematopoiesis and cell survival. For instance, reduced histone acetylation in genes critical for hematopoietic stem cell function can lead to their silencing, impairing bone marrow function. Similarly, increased HDAC activity can exacerbate gene repression, contributing to the pathogenesis of AA by preventing the expression of genes necessary for normal blood cell production.[58-62]

Histone methylation involves the addition of methyl groups to lysine or arginine residues on histone tails. This modification can either activate or repress transcription, depending on the specific residues modified and the degree of methylation. For example, trimethylation of histone H3 on lysine 4 (H3K4me3) is generally associated with active transcription, whereas trimethylation of histone H3 on lysine 27 (H3K27me3) is linked to transcriptional repression. In AA, abnormal histone methylation patterns can disrupt normal gene expression. For instance, altered levels of H3K4me3 or H3K27me3 can lead to the silencing of genes essential for hematopoietic stem cell maintenance and differentiation. These disruptions can impair bone marrow function and contribute to the development of AA. Histone phosphorylation involves the addition of phosphate groups to serine, threonine, or tyrosine residues on histone tails. This modification is associated with various cellular processes, including DNA repair, cell division, and gene regulation. For example, phosphorylation of histone H3 on serine 10 (H3S10ph) is linked to mitotic chromosome condensation and transcriptional activation.[63-67]

In AA, altered histone phosphorylation patterns can affect cell cycle regulation and gene expression. Dysregulated phosphorylation may impair hematopoietic cell proliferation and survival, contributing to bone marrow failure and the progression of AA. Histone ubiquitination

involves the attachment of ubiquitin molecules to lysine residues on histone proteins. This modification can influence gene expression by affecting histone stability and chromatin structure. For instance, ubiquitination of histone H2A is often associated with transcriptional repression, while ubiquitination of histone H3 can be linked to transcriptional activation. In AA, abnormal histone ubiquitination patterns can contribute to the dysregulation of genes involved in hematopoiesis. Changes in ubiquitination can impact histone turnover and chromatin accessibility, affecting the expression of genes critical for normal blood cell production and function. HIV infection can exacerbate disruptions in histone modifications by influencing the activity of histone-modifying enzymes. HIV proteins, such as Tat and Vpr, have been shown to interact with histone-modifying complexes, potentially altering histone acetylation, methylation, and phosphorylation patterns. This can lead to abnormal gene expression and contribute to the pathogenesis of AA in HIV-infected individuals. Additionally, HIV-induced inflammation and oxidative stress can affect histone-modifying enzymes and further disrupt histone modifications. The chronic inflammatory environment created by HIV can lead to global changes in histone modifications, impacting genes involved in immune responses and hematopoiesis.[68-72]

Non-Coding RNAs in Aplastic Anemia and HIV

Non-coding RNAs (ncRNAs) are a diverse group of RNA molecules that do not code for proteins but play critical roles in regulating gene expression and cellular processes. Among the different types of ncRNAs, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) have emerged as key players in the pathogenesis of various diseases, including aplastic anemia (AA) and HIV infection. miRNAs are small, single-stranded RNA molecules approximately 22 nucleotides in length. They regulate gene expression post-transcriptionally by binding to complementary sequences in target mRNAs, leading to their degradation or inhibition of translation. miRNAs play crucial roles in various biological processes, including hematopoiesis, immune responses, and disease development. In AA, miRNA dysregulation can significantly impact hematopoiesis and contribute to disease pathology. For example, aberrant expression of miRNAs can influence the proliferation, differentiation, and survival of hematopoietic stem cells (HSCs). Specific miRNAs, such as miR-21, miR-24, and miR-155, have been found to be dysregulated in AA and are implicated in the pathogenesis of the disease. These miRNAs can target genes involved in cell cycle regulation, apoptosis, and immune modulation, thereby affecting bone marrow function and contributing to AA.[73-78]

HIV infection can alter the expression of miRNAs, affecting both viral replication and host cell function. HIV proteins, such as Tat and Nef, can modulate the expression of host miRNAs, impacting immune responses and hematopoiesis. For instance, HIV-induced changes in miRNA expression can influence the immune response, promote viral persistence, and affect the development of AA in HIV-infected individuals. miRNAs such as miR-17-92 and miR-29 have been implicated in HIV pathogenesis and can also play a role in the development of AA. lncRNAs are longer RNA molecules, typically more than 200 nucleotides in length, that regulate gene expression through various mechanisms. lncRNAs can interact with chromatin-modifying complexes, transcription factors, and other ncRNAs to influence gene expression and cellular processes. In AA, dysregulated lncRNAs can impact hematopoiesis and contribute to disease development. lncRNAs can modulate gene expression by influencing chromatin remodeling,

transcriptional activation or repression, and splicing. For example, lncRNAs such as **HOTAIR** and **MEG3** have been shown to be involved in the regulation of genes associated with hematopoietic stem cell function and bone marrow failure. Aberrant expression of these lncRNAs can disrupt normal hematopoiesis and contribute to the pathogenesis of AA.[79-82]

HIV infection can also affect the expression of lncRNAs, impacting both viral replication and host cellular processes. HIV can induce changes in lncRNA expression that affect immune responses, cellular stress responses, and the development of AA. lncRNAs such as **NEAT1** and **MALAT1** have been implicated in HIV pathogenesis and can influence the progression of AA in HIV-infected individuals. These lncRNAs can interact with various cellular pathways, including those involved in inflammation and immune regulation, potentially exacerbating the effects of HIV on bone marrow function. miRNAs and lncRNAs exert their effects through various mechanisms. miRNAs typically bind to the 3' untranslated regions (UTRs) of target mRNAs, leading to their degradation or inhibition of translation. This post-transcriptional regulation can have broad effects on gene expression and cellular processes. lncRNAs can recruit chromatin-modifying enzymes to specific genomic regions, influencing histone modifications and DNA methylation. lncRNAs can interact with transcription factors and other regulatory proteins to modulate gene expression. lncRNAs can influence alternative splicing of pre-mRNA, affecting the production of different protein isoforms.[83-78]

Conclusion

Non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), play essential roles in regulating gene expression and cellular processes relevant to the pathogenesis of aplastic anemia (AA) and HIV infection. The dysregulation of these ncRNAs can significantly impact hematopoiesis and exacerbate the effects of HIV, contributing to the development and progression of AA. In AA, both miRNAs and lncRNAs are involved in modulating the function of hematopoietic stem cells and bone marrow microenvironments, influencing key processes such as cell proliferation, differentiation, and survival. The aberrant expression of specific miRNAs and lncRNAs can disrupt these processes, leading to impaired blood cell production and increased susceptibility to bone marrow failure. In the context of HIV, the virus can alter ncRNA expression, further complicating the disease by affecting immune responses and promoting the development of AA.

References

1. Furlong E, Carter T. Aplastic anaemia: Current concepts in diagnosis and management. Journal of paediatrics and child health. 2020;56(7):1023-1028.
2. Chichetto NE, Polanka BM, So-Armah KA, Sung M, Stewart JC, Koethe JR, Edelman EJ, Tindle HA, Freiberg MS. Contribution of behavioral health factors to non-AIDS-related comorbidities: an updated review. Current HIV/AIDS Reports. 2020; 17:354-372.
3. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV, 2024; 2(1): 65-78
4. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).

Citation: Obeagu EI. Aplastic Anemia in HIV: The Role of Epigenetic Modifications. *Elite Journal of Haematology, 2024; 2(9):* 33-45

5. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 46-58
6. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(1):21-31
7. Obeagu EI, GU Obeagu. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health, 2024; 2 (1): 8-22
8. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com. 2024;12(01).
9. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine, 2024;2(1): 35-46
10. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology, 2024; 2(1): 34-46
11. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV, 2024; 2(1): 1-15
12. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science, 2024; 2(1): 33-42
13. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology, 2024; 2(1): 47-64
14. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology, 2024; 2(1): 1-13
15. Felker-Kantor EA, Wallace ME, Madkour AS, Duncan DT, Andrinopoulos K, Theall K. HIV stigma, mental health, and alcohol use disorders among people living with HIV/AIDS in New Orleans. Journal of urban health. 2019; 96:878-888.
16. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Asian J Dental Health Sci 2024;4(1):38-44. Available from: http://ajdhs.com/index.php/journal/article/view/63
17. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV, 2024; 2(2): 1-17
18. Obeagu EI, Obeagu GU.Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health, 2024; 2 (1): 22-34
19. Skalski LM, Sikkema KJ, Heckman TG, Meade CS. Coping styles and illicit drug use in older adults with HIV/AIDS. Psychology of Addictive Behaviors. 2013;27(4):1050.
20. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine, 2024; 2(2):104-115
21. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS spread: impact of religious leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.

Citation: Obeagu EI. Aplastic Anemia in HIV: The Role of Epigenetic Modifications. *Elite Journal of Haematology, 2024; 2(9):* 33-45

22. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.
23. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-7.
24. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV infection and cardiovascular diseases: the obnoxious duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.
25. Hill K, Kuo I, Shenoi SV, Desruisseaux MS, Springer SA. Integrated care models: HIV and substance use. Current HIV/AIDS Reports. 2023;20(5):286-295.
26. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 33-45
27. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22
28. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian J Dental Health Sci [Internet]. 2023 Jun. 15 [cited 2024 Sep. 7];3(2):7-14. Available from: http://ajdhs.com/index.php/journal/article/view/39
29. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):9-19.
30. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30
31. Alum EU, Obeagu EI, Ugwu OP, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine. 2023 Oct 13;102(41):e35673.
32. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review, 2024; 2(1): 37-50
33. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
34. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
35. Goodwin M. Black markets: the supply and demand of body parts. Cambridge University Press; 2006.
36. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32
37. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41

38. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
39. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64
40. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda . Elite Journal of Medicine, 2024; 2(1): 1-16
41. Mandania EW. Haematological and Immunological Abnormalities in People Living With HIV: A Review. Journal of Medical and Biomedical Laboratory Sciences Research. 2024;4(1).
42. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 24-36
43. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.
44. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV, 2024; 2(3): 14-26
45. Obeagu EI, Elamin EAI Obeagu GU. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2(3): 111-117
46. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73
47. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology, 2024; 2(2): 43-59
48. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Applied Sciences (NIJBAS). 2023;3(3).
49. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58
50. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-35
51. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2(3): 42-57
52. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17
53. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20-35

Citation: Obeagu EI. Aplastic Anemia in HIV: The Role of Epigenetic Modifications. *Elite Journal of Haematology, 2024; 2(9):* 33-45

54. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science, 2024; 2(2): 5-15
55. American Psychiatric Association. Practice guideline for the treatment of patients with HIV/AIDS. American Psychiatric Pub; 2000.
56. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
57. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science, 2024; 2(3): 59-72
58. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63
59. Sukumaran RK. Long-Term Follow-Up and Chronic Complications. Contemporary Bone Marrow Transplantation. 2021:641-665.
60. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24
61. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health, 2024; 2 (1): 35-51
62. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology, 2024; 2(2): 15-28
63. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology, 2024; 2(3): 33-44
64. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 84-99
65. Lyimo RA, Stutterheim SE, Hospers HJ, de Glee T, van der Ven A, de Bruin M. Stigma, disclosure, coping, and medication adherence among people living with HIV/AIDS in Northern Tanzania. AIDS patient care and STDs. 2014;28(2):98-105.
66. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60
67. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18
68. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. Elite Journal of Laboratory Medicine, 2024; 2(2): 30-46
69. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV, 2024; 2(2): 43-59
70. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2(3): 25-41
71. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 16-29

Citation: Obeagu EI. Aplastic Anemia in HIV: The Role of Epigenetic Modifications. *Elite Journal of Haematology, 2024; 2(9):* 33-45

72. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 33-46
73. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review, 2024; 2(1): 1-16
74. Banerjee N, Goodman ZT, McIntosh R, Ironson G. Cognition, coping, and psychological distress in HIV. AIDS and Behavior. 2022;26(4):1074-1083.
75. Grau LE, Griffiths-Kundishora A, Heimer R, Hutcheson M, Nunn A, Towey C, Stopka TJ. Barriers and facilitators of the HIV care continuum in Southern New England for people with drug or alcohol use and living with HIV/AIDS: perspectives of HIV surveillance experts and service providers. Addiction science & clinical practice. 2017; 12:1-4.
76. Yu Y, Luo D, Chen X, Huang Z, Wang M, Xiao S. Medication adherence to antiretroviral therapy among newly treated people living with HIV. BMC public health. 2018; 18:1-8.
77. Li H, Wu X, Shen J, Lou S. Perspective and experience of patients with aplastic anemia on medication adherence. Patient preference and adherence. 2023:2215-2225.
78. Beichler H, Grabovac I, Dorner TE. Integrated care as a model for interprofessional disease management and the benefits for people living with HIV/AIDS. International Journal of Environmental Research and Public Health. 2023;20(4):3374.
79. Rajabiun S, Tryon J, Feaster M, Pan A, McKeithan L, Fortu K, Cabral HJ, Borne D, Altice FL. The influence of housing status on the HIV continuum of care: results from a multisite study of patient navigation models to build a medical home for people living with HIV experiencing homelessness. American Journal of Public Health. 2018;108(S7):S539-45.
80. Dale SK, Safren SA. Striving towards empowerment and medication adherence (STEP-AD): a tailored cognitive behavioral treatment approach for black women living with HIV. Cognitive and Behavioral Practice. 2018;25(3):361-376.
81. Ngcobo S, Scheepers S, Mbatha N, Grobler E, Rossouw T. Roles, barriers, and recommendations for community health workers providing community-based HIV Care in Sub-Saharan Africa: a review. AIDS Patient Care and STDs. 2022;36(4):130-144.
82. Obeagu EI, Ogu RIO, Ngwoke AO. Psychosocial Impact of Aplastic Anemia Diagnosis in HIV Patients: A Narrative Review. Elite Journal of Public Health, 2024; 2 (7): 35-46
83. Obeagu EI, Akinleye CA. Stabilizing Hemoglobin Levels: A Vital Aspect of Blood Transfusions in HIV Management. *Elite Journal of Haematology, 2024; 2(9):* 1-8
84. Obeagu EI, Akinleye CA. Promoting Fertility: Blood Transfusions and Reproductive Health in HIV-Positive Individuals. *Elite Journal of Haematology, 2024; 2(9):* 9-16
85. Obeagu EI, Akinleye CA. Minimizing Treatment-Related Depression: Blood Transfusions and Mental Health Support in HIV Care. Elite Journal of Public Health, 2024; 2 (7): 16-24
86. Obeagu EI, Akinleye CA. Promoting Social Integration: Blood Transfusions and Improved Social Well-being in HIV Patients. Elite Journal of Public Health, 2024; 2 (7): 25-34
87. Obeagu EI, Akinleye CA. Optimizing Physical Endurance: Blood Transfusions in HIV and the Improvement of Exercise Capacity. Elite Journal of Medicine, 2024; 2(9): 1-9

Citation: Obeagu EI. Aplastic Anemia in HIV: The Role of Epigenetic Modifications. *Elite Journal of Haematology, 2024; 2(9):* 33-45